[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
Ethics::
peer-review::
Indexing::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Journal DOI

AWT IMAGE

..
Copyright Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 
This Journal is licensed under a Creative Commons Attribution-NonCommercial 4.0
..
:: Volume 19, Issue 9 (9-2017) ::
J Babol Univ Med Sci. 2017; Volume 19 Back to browse issues page
The Renoprotective Effects of Sodium Valproate as a Histone Deacetylase Inhibitor on Diabetic Nephropathy
R Ataee , H Esmaeeli *
Department of Science and Technology, Mazandaran University of Medical Sciences, Sari, I.R.Iran , esipharm@yahoo.com
Abstract:   (4716 Views)

BACKGROUND AND OBJECTIVE: Diabetic nephropathy (DN), as the most common cause of end-stage renal failure, caused by protein kinase C pathway and reactive oxygen species. Recent studies demonstrated importance of epigenetic processes such as histone acetylation and the role of histone deacetylases (HDAC) and histone acetyltransferase in the development of this silent epidemic. Sodium valproate (VA) is known as a histone deacetylase inhibitor(HDACi). DN must be prevented and treated because it is prevalent and important.
METHODS: In this study, scientific articles indexed in databases "Web of science, Scopus, PubMed, SID, ISI" were studied using key words "Sodium Valproate, Diabetic Nephropathies, Histone Deacetylase Inhibitors".
FINDINGS: VA can prevent the degradation podocytes and renal cells through the autophagy and reduce proteinuria in the DN condition. In addition, VA, as an HDAC, prevented apoptosis of podocytes, thus it improves DN. Because HDAC class I involved in renal fibrogenesis and fibroblast activation by modulation of TGF-β signaling, sodium valproate promotes antifibrotic effects logically. VA can regulate NF-κB signaling, thereby exert an anti-inflammatory effect in podocytes.  HDAC inhibition decreased eNOS mRNA but paradoxically increased activity of eNOS promoter, probably because of inducing an eNOS mRNA-destabilizing factor. Sodium valproate as a HDACi has the high renoprotective effect in laboratory studies with DN models.
CONCLUSION: It is expected that sodium valproate will be used as the prevention or treatment of DN in the future after the clinical trials.

Keywords: Sodium Valproate, Diabetic Nephropathies, Histone Deacetylase Inhibitors
Full-Text [PDF 326 kb]   (1956 Downloads)    
Type of Study: Review | Subject: Pharmacology
Received: 2017/03/23 | Accepted: 2017/09/27 | Published: 2017/10/4
Send email to the article author



XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ataee R, Esmaeeli H. The Renoprotective Effects of Sodium Valproate as a Histone Deacetylase Inhibitor on Diabetic Nephropathy. J Babol Univ Med Sci 2017; 19 (9) :45-53
URL: http://jbums.org/article-1-6703-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 19, Issue 9 (9-2017) Back to browse issues page
مجله علمی دانشگاه علوم پزشکی بابل Journal of Babol University of Medical Sciences

The Journal of Babol University of Medical Sciences is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Persian site map - English site map - Created in 0.05 seconds with 42 queries by YEKTAWEB 4645